Related Experiment Videos

Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective

Angelika Aurbach1, Wolfgang Russ, Edouard Battegay

  • 1InForMed GmbH--Outcomes Research and Health Economics, Ingolstadt, Germany. a.aurbach@informed.de

Swiss Medical Weekly
|September 25, 2004
PubMed

Insights

Ramipril is a cost-effective treatment for high-risk cardiovascular patients in Switzerland, offering significant value. It proves even more cost-effective for diabetic patients, optimizing healthcare resource use.

Area of Science:

  • Cardiovascular medicine
  • Health economics
  • Pharmacoeconomics

Background:

  • Ramipril may prevent cardiovascular events in high-risk individuals.
  • This study evaluates ramipril's cost-effectiveness for high-risk patients in Switzerland.
  • Diabetic patients were analyzed as a specific subgroup.

Purpose of the Study:

  • To assess the cost-effectiveness of ramipril versus placebo in high-risk cardiovascular patients.
  • To determine the cost-effectiveness specifically within the diabetic patient subgroup.
  • To analyze the economic impact from a third-party payer's perspective.

Main Methods:

  • A decision analytic cost-effectiveness model was developed.
  • Clinical data were sourced from the HOPE study; cost data from literature.
  • Sensitivity analyses, including Monte Carlo simulation, were performed to assess robustness.

Main Results:

  • The incremental cost-effectiveness ratio was CHF 6,005 per life-year gained (LYG) for ramipril vs. placebo.
  • In diabetic patients, the ratio was significantly lower at CHF 3,790 per LYG.
  • Sensitivity analyses showed moderate impact of price variations on cost-effectiveness.

Conclusions:

  • Ramipril represents an efficient use of healthcare resources for high-risk cardiovascular patients in Switzerland.
  • The drug is particularly cost-effective in the subgroup of diabetic patients.
  • Ramipril is a valuable therapeutic option under reasonable economic assumptions.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...